White Cell Differential Patents: Who Leads, Where the Gaps Are 2026
White cell differential methods: patents behind leukocyte classification and flow-based differential counting
74.1% concentration. The top five ranked assignees hold 197 of the 266 records in scope — a field where claim space is already tightly held near the top. Filings ran from 6 in 2017 to a peak of 13 in 2023, before tapering toward 2026. The most recent one to two years will read low on any chart of this kind — publication typically lags filing by around 18 months, so 2025 and 2026 figures are still filling in.
- 1IRIS INTERNATIONAL INC93
- 2ABBOTT LAB INC46
- 3BECTON DICKINSON & CO26
- 4BECKMAN COULTER INC16
- 5ACCELLIX LTD16
See the full white cell differential methods analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Frequently asked questions
Who holds the most patents in white cell differential methods?
The assignee ranking in this dataset is led by a single company with 93 of the 266 records in scope, well ahead of the fifth-ranked assignee at 16 and the tenth-ranked assignee at 9. The top five ranked assignees together hold 197 records, or 74.1% of all 266 records, and the top ten hold 93.6%. That means most freedom-to-operate analysis in this field should start with the leading holder’s portfolio rather than treating filings as evenly spread across the market.
What technologies dominate white cell differential patent filings?
Material analysis and testing (IPC class G01N) appears in 94.7% of the 266 records in scope, making it by far the dominant classification. Mixing apparatus (B01F, 8.6%), lab apparatus (B01L, 7.5%) and bioreactor or enzyme apparatus (C12M, 5.3%) follow well behind, with optics (G02B) and image processing (G06T) each under 4%. Because a single record can carry several IPC classes, these shares add up to more than 100%, and they should be read as coverage intensity rather than a breakdown of the whole field.
Is the white cell differential patent space still growing?
Filing activity in this dataset ran from 6 records in 2017 to a peak of 13 in 2023, with the count tapering toward the 2026 data cut-off. A precise growth rate is not computable from this data because fewer than four complete years remain once publication lag is accounted for, and the 2025-2026 figures will read artificially low simply because publication typically lags filing by around 18 months. Readers should treat the last one to two years of any trend chart as provisional rather than a real drop-off.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on White Cell Differential Methods covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.